Maplelane Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Maplelane Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-75,558	Closed	-$1.71M	–	134
2014 Q2	$1.71M	Sell	75,558 -52,342	-41%	-$1.09M	0.11%	94
2014 Q1	$3.11M	Buy	+127,900	New	+$3.24M	0.1%	103

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Maplelane Capital's ACAD Position: Q3 2014 in Review

Maplelane Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2014, closing a stake of 75,558 shares — an estimated $1.71M sold.

Maplelane Capital first reported a position in ACAD in Q1 2014 and held it in 2 quarters. The position peaked at $3.11M in Q1 2014. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

Maplelane Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Maplelane Capital sold 75,558 Acadia Pharmaceuticals shares in Q3 2014, an estimated $1.71M.
Maplelane Capital first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 2 quarters.
Maplelane Capital's Acadia Pharmaceuticals position peaked at $3.11M in Q1 2014.
162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on Maplelane Capital's 13F filing for Q3 2014, filed 14 Nov 2014.